Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS [Yahoo! Finance]
Biogen (NASDAQ:BIIB) was downgraded by analysts at Hsbc Global Res from a "hold" rating to a "moderate sell" rating.
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wells Fargo & Company from $155.00 to $190.00. They now have an "equal weight" rating on the stock.
Biogen (NASDAQ:BIIB) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.